PCT/GB 2004 / 0 0 5 1 5 6

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed Andrew Gersey

Dated 31 December 2004

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

SPG/P103967GB

2. Patent application number
(The Patent Office will fill in this part)

0329310.7

18 DEC 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Keele University
KEELE
Staffordshire
ST5 5BG

Patents ADP number *(if you know it)* 61014630001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Method

5. Name of your agent *(if you have one)*

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

31 St Saviourgate
YORK
YO1 8NQ

Patents ADP number *(if you know it)* 07914237002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	22
Claim(s)	24
Abstract	
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature S.P. Gilholm Date 18 Dec 2003

12. Name and daytime telephone number of person to contact in the United Kingdom S P Gilholm 01904 732120

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0845 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

Method

This invention relates to a novel method of magnetically manipulating stem cells ex vivo or *in vivo* and to methods of treatment related thereto.

The use of stem cells in the form of a cell-based therapies is currently one of the most exciting and promising areas for disease treatment and reparative medicine. Clearly, basic research into the ways by which proliferation and differentiation of e.g. embryonic and adult stem cells can be controlled is vitally important.

US Patent No. 6,548,264 describes silica coated nanoparticles which comprise a magnetic metal core. The magnetic core present in the particles enables the particles to be responsive to a magnetic field and therefore, the particles are suitable for use in diagnostic, imaging and recording systems. However, the nanoparticles of the prior art may suffer from the disadvantage that they do not define the method of activation at a cellular level.

Magnetic bead twisting cytometry has been used to define the mechanical properties of single cells and to demonstrate that external mechanical forces can be transmitted across the cell surface and through the cytoskeleton via transmembrane cell adhesion molecules such as integrins, see, for example, Wang, N and Ingberger, DE (1995) Probing transmembrane mechanical coupling and cytomechanics using magnetic twisting cytometry. *Biochem. Cell Biol.* 73: 327-335.

There have been many developments in biocompatible magnet nanoparticle synthesis, characterization[1-3] and applications of novel magnetic techniques in the field of healthcare[4-6]. This work primarily has involved investigating the controlled and directed transport of pharmaceuticals. In these systems therapeutic drugs or genes may be attached to magnetic carrier particles (usually polymer coated magnetite), which are then concentrated at the target site *in vivo* by the application of spatially focused, high gradient magnetic fields. Once the drug/carrier complexes

have accumulated at the target site, the drug is released and uptake at the sites is enhanced. Investigations have been made into new methods for magnetic targeting for gene therapy as well as theoretically and experimentally examining and improving deposition of magnetic micro- and nanoparticle carriers in model systems *in vitro* and *in vivo*[4,6].

Short-term experiments where force is applied to the cell membrane using torque or where tension is applied to transmembrane proteins such as RGD or collagen molecules has been described by a number of researchers[7,8]. These experiments use 'mechanical' stimulation of the membrane to trigger short term internal calcium fluxes in a variety of cells. It is known that mechanical signalling using other techniques can trigger differentiation pathways in bone marrow stromal cells down the osteogenic lineage[11] and in particular, that low level mechanical signals across the membrane can up-regulate expression and DNA binding activity of osteoblastic specific transcription factors, cbfal and cfos[12,13].

In these investigations, force can be applied to a number of different tagged receptors. It has been demonstrated how we can influence downstream processes and enhance collagen and other matrix protein synthesis[15]. Using bone marrow derived mesenchymal stem cells conditioned to differentiate along the osteogenic and chondrogenic lineage we have been investigating downstream gene regulation in response to magnetic particle activation of specific receptors. Preliminary data has shown an up-regulation in Runx 2 in response to magnetic particle stimulation of calcium channels in human mesenchymal stem cells followed by up-regulation of a mechanosensitive matrix protein, osteopontin. In addition, we have evidence of up-regulation of SOX 9 following stimulation of monolayer human dedifferentiated chondrocytes. These studies have been extended to 3D analysis of cell-seeded scaffolds over long-term culture to investigate the use of these strategies for construct fabrication in tissue engineering *in vitro*. Furthermore, preliminary studies which include a dose-response analysis of particle number and force applied are

encouraging and indicate increased matrix synthesis and expression of the osteogenic phenotype[14].

Bone marrow contains multipotential stromal stem cells or mesenchymal stem cells which can differentiate into, *inter alia*, fibroblastic, osteogenic, adipogenic and reticular cells. These mesenchymal stem cells, such as human bone marrow stromal fibroblasts can be isolated from volunteer donors and may retain their multilineage (adipocytic, chondrogenic, osteoblastic) potential. One advantage in the use and manipulation of the aforementioned cells lies in their lack of immunogenicity which provides the potential for use of these cells in, *inter alia*, cartilage and bone repair.

Our as yet unpublished co-pending International Patent Application, No. PCT/GB2003/ 002624 combines the magnetic nanoparticle approach with knowledge of mechanosensitive ion channels, in particular, the TREK K+ channel. It is established that the TREK channel is present in osteogenic, chondrogenic and bone marrow stromal cells In order to define more closely the targeting of specific receptors to control activation, we have used HIS-tagged clones of the TREK gene. HIS tags have been inserted into particular regions of the TREK molecule to allow attachment of HIS antibody or NI^{2+} bound magnetic particles which can then be remotely torques using a magnetic field. Sites of the ion channel protein which lie both internal and external to the cell membrane have been tagged and in this way we can identify the mechanosensitive regions of the molecule as well as define the signal frequencies required to switch on downstream processes. Figure 2 shows the results of experiments using bone marrow stromal cells with internal calcium levels up-regulated as a result of the application of magnetic fields to magnetic nanoparticles attached to a His-tagged TREK channel.

It has been shown that conditioning connective tissue cells *in vitro* can be achieved, by, *inter alia*, the development of a magnetic force bioreactor which enables magnetic fields to be applied *in vitro* to 2D monolayer cultures and 3D cell-seeded scaffolds.

However, neither US '264 nor Wang solve or even address the problems surrounding two fundamental questions which need to be addressed, and which encompass the ultimate goal of engineering cells for clinical use, namely;

(i) how will cells be targeted to the site of repair and held at that site; and

(ii) how will cells e.g. stem cells, be conditioned or differentiated *in vitro* and/or *in vivo*.

We have now surprisingly found ways by which stem cells tagged with magnetic nanoparticles can be delivered to or held at, a particular repair site by external magnetic manipulation. In addition, we have developed these concepts further to include remote activation of specific cellular membrane receptors, which in essence, involves localising cells e.g. stem cells. More simply this involves deposition of stem cells at a site e.g. a repair site, retaining the cells at the site and remotely activating the cells *in situ* within the patient.

In particular, the present invention addresses issues of targeting specific receptors on cells for remote activation of transmembrane ion channels in stem cells. Importantly, magnetic nanoparticle-based technologies are increasingly used clinically, in many facets of healthcare e.g. contrast enhancement for MRI.

In the present invention we have achieved early stages of differentiation of these cell types. Moreover, the achieved differentiation acts as a model for binding strategies which allows both remote targeting within the body and/or activation at specific sites when localised.

Thus, the present invention enables the targeting of a variety of stem cell receptor types, such as mechano-activated ion channels e.g. K+ channels (TREK), calcium channels, integrins and surface membrane binding sites such as RGD, present in

human bone marrow stem cells. Importantly, such receptors have the potential for remote activation. The targeting of other known receptors, such as external growth factors (e.g. TGFB and BMP2) which have been shown to activate downstream transcription factors such as Runx2 and Osterix, critical for stem cell differentiation can also be achieved.

Thus, the present invention provides the opportunity for true engraftment of, *inter alia*, human mesenchymal stem cells, long-term biological effects on the stem cells at the site of injury or repair. Furthermore, the ability to select, expand and differentiate these cells and target the cells using magnetic nanopartioles is especially advantageous. Furthermore, utilisation of the present invention provides therapeutic implications in, inter alia, gene therapy and tissue engineering.

Biocompatible magnetic nanoparticles, primarily composed of a magnetite (Fe_3O_4) and/or maghemite (Fe_2O_3) core with either a silica, dextran, or PVA coating may be utilised in the present invention. Such particles may be synthesized following methods known in the art. However, it will be understood that other magnetic nanopartioles may be utilised. Particle sizes can range from ~10nm up to a few microns e.g. 1 to 10μm. Commercially available magnetic micro- and nanoparticles with varying surface chemistry may also be used. The coatings may be functionalized and crosslinked to membrane attachment motifs such as those described above. The magnetic nanoparticles may be modified so as to customise, *inter alia*, particle internalization frequency and binding efficiency and stability will be examined as will the effects of binding on cell viability and function. Modification may also include customisation of internal binding sites as well as sites on the outer membrane. A variety of coatings may be used in magnetic nanoparticle binding and loading in human osteoblasts[14,15] and these techniques may be further optimized for stem cell binding, delivery and activation e.g. using adult primary marrow human stem cells and/or human embryonic stem cells.

Targeting

Conventionally known high gradient magnets, e.g. external rare earth (primarily NdFeB), high-gradient magnets, may be used to target the stem cells to specific sites within an *in vitro* test system and/or *in vivo*. Clearly, it is a preferred aspect of the invention to target the stem cells *in vivo*. Such magnets produce high field/gradient products which exert a translational force on the magnetic particles loaded onto the cells, holding them at the target site according to the equation:

$$F_{mag} = (X_2 - X_1) V \frac{1}{\mu_o} B(\nabla B)$$

Activation

Remote mechanical activation may be achieved using e.g. a magnetic conditioning bioreactor. Such bioreactors, which are known *per se*, enable forces to be applied to magnetic particles attached to cells cultured *in vitro* within a multi-well 2D system or *in vivo* a 3D scaffold-based system. Stem cells, e.g. Mesenchymal stem cells and populations generated therefrom, such as osteogenic, chondrogenic and adipogenic populations may be isolated using, for example, magnetic activated cell sorting (MACS) with a monoclonal antibody e.g. STRO-1 using standard protocols known *per se*[14]. Such protocols include those known for BMSc culture in monolayer and using 3D scaffolds composed of biodegradable polymers such as poly lactic acid (PLLA) or collagen gels[21].

We have now found a method of selectively activating and/or targeting stem cells which enables the cells to then be manipulated mechanically in a remote manner.

By the term "in a remote manner" it is intended to mean, e.g. a non-contacting manner and in the case of *in vivo* activating/targeting specifically from outside the body.

Thus according to the invention we provide a method of magnetically manipulating a stem cell *in vivo* or *in vitro* which comprises the association of a magnetisable particle with a stem cell.

The method may comprise *ex vivo* manipulation of an *in vivo* process. Furthermore, it will be understood by the skilled man that a reference to a cell shall be construed to include a plurality of cells.

More particularly, the invention provides a method as hereinbefore described which comprises the activation and/or targeting of a magnetisable particle with a stem cell as hereinbefore described.

According to a further aspect of the invention we provide a method of magnetically manipulating a stem cell which comprises the association of a magnetisable particle with a cell characterised in that the method comprises agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell.

According to a yet further aspect of the invention we provide a method as hereinbefore described which include a differentiation step.

In this aspect of the invention the magnetisable particle may be associated directly with the cell. Alternatively, the method may comprise associating the magnetisable particle with an antibody, enzyme, etc., which is subsequently associated with the cell.

The association of a magnetisable particle with a cell may comprise the introduction of such a particle into a cell, the attachment of such a particle to a cell, e.g. externally or internally to a cell, or any combination thereof. Thus, the magnetisable particles may be associated intracellularly or extracellularly or a combination of intracellularly and extracellularly. However, in a preferred aspect of the invention the particles are associated intracellularly.

When the method of the invention comprises intracellular association this will comprise association with an internal binding site. By way of example only, for TREK-1, the particle(s) may be associated with the N-terminus region of the ion channel. Alternatively, the particle(s) may be associated with the COOH terminus region of the ion channel. It will be appreciated by one skilled in the art that numerous ion channels and binding sites may be utilised in the method of the invention. Thus, internal binding sites which correspond to the N-terminus region of the ion channel, as seen in TREK-1or which corresponds to the COOH terminus region of the ion channel. as seen in TREK-1 may be utilised as well as other binding sites known *per se*.

Thus, we also provide a method of manipulating a mechanosensitive ion channel characterised in that the method comprises the association of a magnetisable particle with an ion channel, either directly or indirectly.

The method of the invention may comprise the manipulation of mammalian cells or other cell types, such as bacterial cells, plant cells, etc. However, it will be understood by the skilled man that the method of the present invention may be used to manipulate other cell types not mentioned herein. Furthermore, the method may be an *in vitro* method or an *in vivo* method, although an *in vivo* method is preferred.

Preferentially, the method of the invention comprises the remote manipulation of cells and/or of agonising or antagonising ion channels, e.g. manipulation from outside the body., i.e. remote mechanical activation.

The method of the invention may be utilised in relation to a variety of cells which are known *per se*. However, preferentially, the method is suitable for use with mammalian stem cells.

The method of the invention may be utilised in connection with any conventionally known ion channels within the cell which are hereinbefore described. The method is especially suited for use in mechanosensitive ion channels. Such mechanosensitive ion channels have been identified in many cell types and have been predominantly described as calcium or potassium ion channels, although it should be understood that the method of the invention is not limited to use in relation to calcium or potassium ion channels. By way of example only, one such channel which has been well characterised at the molecular level and at the functional level in neuronal cells is the chromosomal gene TREK-1, which is part of the 2P K+ channel family. TREK-1 channels, have been identified in bone cells, and are known to respond to shear stress, cell swelling and membrane stretch as well as other external agents such as fatty acids and general anaesthetics.

A particular aspect of the present invention is to provide a method of manipulating mechanosensitive ion channels.

These "mechanosensitive" ion channels are present in a variety of mammalian, e.g. human, and bacterial cells and the present invention enables the cells to be selectively activated in the body and/or in cell cultures, see, for example, Sokabe, M, F Sachs, A Jing (1991) Quantitative video microscopy of patch clamped membranes: Stress, strain, capacitance, and stretch channel activation. *Biophys J.* 59: 722-728; Stewart, Z, B Martinac and J Dobson (2000) Evidence for mechanosensitive transmembrane ion channels of small conductance in magnetotactic bacteria. *Electro- and Magnetobiol.* 19: 81-89. As these channels are instrumental in normal cellular function and play a particularly important role in, for example, the production of bone and connective tissue or activation of the peripheral nervous system, the ability to manipulate them remotely, e.g. from outside the body, is especially advantageous an provides applications in, *inter alia*, pain relief, e.g. anaesthetics, therapeutics, tissue engineering and repair and cancer therapy.

In a further aspect of the invention the method may also be suitable for use with conventionally non mechanosensitive cells and/or ion channels by the transfection of channels into cells which may otherwise be otherwise non-responsive.

All ion channels open and close (i.e. change conformational state) in response to forces and this is the principle behind ion channel activation. In the case of mechanosensitive ion channels, the force results in membrane deformation, triggering the opening of the channel. Voltage-gated and ligand-gated ion channels are also "mechanoresponsive" in that they respond to mechanical stresses on the ion channel generated by coulomb forces (in the case of voltage-gated channels) and binding forces (in the case of ligand-gated channels). As such, all ion channels can be activated by the method described herein provided that the magnetisable particle is coupled, either directly or indirectly, to the mechanoresponsive region of the channel protein.

Thus, in one aspect of the present invention the ion channel is a voltage-gated ion channel, alternatively, the ion channel is a ligand-gated ion channel.

A wide variety of particles may be used in the method of the invention. The magnetisable particle used in the method of the invention may be inherently magnetic or, alternatively, may be one which reacts in a magnetic field. Generally, any magnetic material may be used, however, by the term magnetic we mean, for example, a material which is paramagnetic superparamagnetic, ferromagnetic and/or antiferromagnetic, examples of which include elemental iron (Fe), or an compound, e.g. an iron salt, such as, magnetite (Fe_3O_4), maghemite (γFe_2O_3), and greigite (Fe_3S_4), or a chromium compound, e.g. a chromium salt, such as chromium oxide (CrO_2), or any combination thereof. Preferably the magnetic material comprises particles, e.g. nanoparticles, which comprises a magnetic core with a biocompatible coating. Thus, such preferred particles are nanoparticles and especially nanoparticles having a core and, e.g. a silica shell enveloping the core. However, also porous particles with multiple magnetic centres within the pores. An example of such

particles are those nanoparticles described in US Patent No. 6,548,264 which is incorporated herein by reference. Thus, the prior art nanoparticles may have a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising a magnetisable particle and (b) a silica shell enveloping the core, wherein the magnetisable particle is a magnetic material as hereinbefore described.

The micro- and nano- particles (intended to be attached to the cells) will generally be substantially spherical or elliptical. The size of the particles may vary according, *inter alia*, to the nature of the magnetisable material, the application, etc. However, an example of particles may be nanoparticles can having a mean size, e.g. diameter, of 5000 nm or less, e.g. from 1 nm to 5000 nm, preferably from 1 nm to 1000 nm, more preferably from 1 nm to 300 nm, or from 2 nm to 10 nm).

The particles for attachment to the cells may be coated or uncoated and single or multi-domain. Examples of suitable particles include, but are not limited to:

(i) Coated magnetic microspheres (d = 4 μm) available from Spherotech, Inc. These microspheres consist of a magnetically blocked core - coated by a polymer.

(ii) Single-domain, ferrite-doped silica nanoparticles with tunable size (d = 50-300 nm) and narrow size distribution.

In the method of the invention the ion channels may be activated by attaching the magnetisable particles as hereinbefore described to specific regions of the cellular membrane and/or to specific "receptors" on the ion channels themselves. Thus, the mechanical forces required to activate the channels can then be applied remotely by a magnetic field acting on these magnetic particles.

In particular the method of the invention comprises modifying a magnetisable particle as hereinbefore described by tagging the particle with one or more specific

antibodies or protein binding motifs which recognise key cellular elements within a cell. These include transmembrane adhesion molecules, such as integrins, cadherins, selectins, and immunoglobulins or dispersed membrane adhesion proteins such as RGD (arginine-glycine-aspartate), see, for example, . J. Chen, B. Fabry, E. L. Schiffrin, and N. Wang (2001) Twisting integrin receptors increases endothelin-1 gene expression in endothelial cells *Am J Physiol Cell Physiol.* **280**: 1475-84 ; A. R. Bausch, U. Hellerer, M. Essler, M. Aepfelbacher, and E. Sackmann (2001) Rapid stiffening of integrin receptor-actin linkages in endothelial cells stimulated with thrombin: a magnetic bead microrheology study *Biophys J* **80**: 2649-57 ; Cartmell, SH, J Dobson, S Verschueren, A El Haj (2002) Development of magnetic particle techniques for long-term culture of bone cells with intermittent mechanical activation. *IEEE Transactions on NanoBioscience* **1**: 92-97.

The method of the invention is especially advantageous because it provides a method of treatment of a variety of disorders. Indeed the invention provides a method of treatment which is applicable to any disorder in which one or more ion channels play a role. In addition, the invention provides a method for potential control of ion channel activation including pain relief, e.g. an anaesthetic role.

Thus according to the invention we provide a method of treatment of a patient suffering from a disorder in which an ion channel plays a role which comprises the administration to such a patient of magnetisable nanoparticles as hereinbefore described and manipulating those particles using a magnetic field.

The method of treatment as hereinbefore described should not be considered to be limited, but it is especially advantageous in tissue and/or bone repair. The method of treatment can be to facilitate further treatment by providing a method of pain relief, e.g. for localised anaesthesia, to targeted regions of the body.

The nature of such cells may vary depending upon the nature of the tissue of interest. For example, the cells may be ligamentum cells for growing new ligaments,

tenocytes for growing new tendon. Alternatively, the cells may be chondrocytes and/or other stromal cells, such as chondrocyte progenitor cells.

Thus the method of the invention may include the regeneration of tissue or the generation of artificial tissue, such as skin, cartilage, ligament, tendon, muscle or bone.

Alternatively the method may comprise wound healing and/or tissue adhesion.

In a preferred embodiment the method may comprise bone repair and/or bone growth.

In a yet further alternative the method of the invention may include, for example, dental applications and/or veterinary applications.

The method also may be used as a mechanism for selectively killing cells (such as tumour cells) *in vivo*. In this case, magnetisable particles are attached to the target cell membrane or ion channel protein and a magnetic field is applied to the *in vivo* target region. The rapid, cyclic opening and closing (via the application of a time varying magnetic field), and/or the holding open (via the application of a static magnetic field) of ion channels in the cell membrane allows ions (such as Ca^{++}) to flood the cell, inducing osmotic shock and, consequently, cell death.

Thus, according to this aspect of the invention we also provide a method of destroying cells or inhibiting cell growth which comprises agonising or antagonising ion channels within a cell which by the association of a magnetisable particle with a cell.

The method may comprise a method of inducing osmotic shock to a cell, e.g. by agonising or antagonising ion channels within a cell by the association of a

magnetisable particle with a cell. The method is especially useful in the treatment or alleviation of a tumour cell, e.g. a cancer cell.

Thus, the method may comprise the killing of cells by holding ion channels open with a targeted static magnetic field. Alternatively, the method may comprise the killing of cells via cyclically opening and closing ion channels with a targeted, time-varying magnetic field.

In the methods of the invention the magnetic field may be varied depending upon, *inter alia*, the nature of the disorder to be treated, but may be, for example, at a frequency of from 0.1 to 10 Hz. But, frequencies outside this range can also be used. The magnetic field will typically have a flux density in the order of (but not limited to) 10 mT to 1400 mT.

In the method of the invention the magnetic field may be generated outside the body for the case of *in vivo* applications, and may be provided by a permanent magnet or an electromagnet. The magnetic field may be a constant or a variable field, e.g. a permanent magnet may be moved relative to the cells. In the case of an electromagnet, a magnetic field may be generated by provision of appropriate electric current levels to the electromagnetic, optionally, in combination with alternating current.

According to a yet further aspect of the invention we provide a method of inducing a therapeutic effect in a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell and magnetically manipulating the magnetisable particle.

In addition we provide a method of treatment which comprises the administration of a therapeutically active agent which may be administered simultaneously, separately or sequentially with a magnetisable particle whilst agonising or antagonising ion channels within the cell.

We also provide a method of targeting a therapeutically active agent to a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell, magnetically manipulating the magnetisable particle and simultaneously, separately or sequentially administering the therapeutically active agent.

According to a yet further aspect of the invention we also provide the use of a magnetisable particle in a method of magnetically manipulating cells *in vivo*

The use may comprise *ex vivo* manipulation of an *in vivo* process. More particularly, the invention provides the use of a magnetisable particle in the manufacture of a system for magnetically manipulating a cell which system comprises the association of a magnetisable particle with a cell and agonising or antagonising ion channels within the cell.

In this aspect of the invention the magnetisable particle may be associated directly with the cell. Alternatively, the use may comprise associating the magnetisable particle with an antibody, enzyme, etc., which is subsequently associated with the cell.

When the use of the invention comprises intracellular association. By way of example only, for TREK-1, the particle(s) may be associated with the N-terminus region of the ion channel. Alternatively, the particle(s) may be associated with the COOH terminus region of the ion channel.

The use of the invention may comprise the manipulation of mammalian cells or other cell types, such as bacterial cells, plant cells, etc. The use may be an *in vitro* use or an *in vivo* use, although an *in vivo* use is preferred.

Preferentially, the use of the invention comprises the remote manipulation of cells and/or of agonising or autagonising ion channels, e.g. manipulation from outside the body, i.e. remote mechanical activation.

The use of the invention may be utilised in relation to a variety of cells, which are known *per se*. However, preferentially, the use is suitable for use with mammalian somatic cells, for example, bone, cartilage, muscle (skeletal and cardiac) lymphatic cells, endocrine cells, urinary system cells, cells relating to the reproduction system, neuronal cells and tumour cells.

The use of the invention may be utilised in connection with any conventionally known ion channels within the cell, which is hereinbefore described. The use is especially suited for use in mechanosensitive ion channels hereinbefore described.

A particular aspect of the present invention is to provide the use in the manufacture of a system for manipulating mechanosensitive ion channels.

In a further aspect of the invention the use may also be suitable for use with conventionally non mechanosensitive cells and/or ion channels by the transfection of channels into cells which may otherwise be otherwise non-responsive.

In one aspect of the present invention the ion channel is a voltage-gated ion channel, alternatively, the ion channel is a ligand-gated ion channel.

A wide variety of particles may be used in the use of the invention. Generally, any magnetisable material may be used, examples of which include elemental iron (Fe), or an iron compound, e.g. an iron salt, such as, magnetite (Fe_3O_4), maghemite (γFe_2O_3), and greigite (Fe_3S_4), or a chromium compound, e.g. a chromium salt, such as, chromium oxide (CrO_2), or any combination thereof. Preferably the magnetic material comprises particles which comprises a magnetic core with a biocompatible coating. Thus, such preferred particles are nanoparticles and especially nanoparticles

having a core and, e.g. a silica shell enveloping the core. However, also porous particles with multiple magnetic centres within the pores. An example of such particles are those nanoparticles described in US Patent No. 6,548,264 which is incorporated herein by reference.

In particular the use of the invention comprises modifying a magnetisable particle as hereinbefore described by tagging the particle with one or more specific antibodies or protein binding motifs which recognise key cellular elements within a cell. These include transmembrane adhesion molecules, such as integrins, cadherins, selectins, and immunoglobulins or dispersed membrane adhesion proteins such as RGD (arginine-glycine-aspartate).

The use of the invention is especially advantageous because it provides a system suitable for use in the treatment of a variety of disorders. Indeed the invention provides the use in the manufacture of a medicament suitable for a treatment, which is applicable to any disorder in which one or more ion channels play a role. In addition, the invention provides the use for potential control of ion channel activation including pain relief, e.g. an anaesthetic role.

Thus, according to the invention we provide the use of a magnetisable particle in the manufacture of a medicament suitable for the treatment of a patient suffering from a disorder in which an ion channel plays a role which comprises the administration to such a patient of magnetisable particles as hereinbefore described and manipulating those particles using a magnetic field.

The use as hereinbefore described should not be considered to be limited, but it is especially advantageous in tissue and/or bone repair. The use can be to facilitate further treatment by providing a method of pain relief, e.g. for localised anaesthesia, to targeted regions of the body.

The nature of such cells may vary depending upon the nature of the tissue of interest. For example, the cells may be ligamentum cells for growing new ligaments, tenocytes for growing new tendon. Alternatively, the cells may be chondrocytes and/or other stromal cells, such as chondrocyte progenitor cells.

Thus, the use may include the regeneration of tissue or the generation of artificial tissue, such as skin, cartilage, ligament, tendon, muscle or bone.

Alternatively the use may comprise wound healing and/or tissue adhesion.

In a preferred embodiment the use may comprise bone repair and/or bone growth.

In a yet further alternative the use of the invention may include, for example, dental applications and/or veterinary applications.

The use also may be used as a mechanism for selectively killing cells (such as tumour cells) *in vivo* as hereinbefore described.

Thus, according to this aspect of the invention we also provide the use of a magnetisable particle in the manufacture of a system for destroying cells or inhibiting cell growth which comprises agonising or antagonising ion channels within a cell which by the association of a magnetisable particle with a cell.
The use may comprise use in a method of inducing osmotic shock to a cell, e.g. by agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell. The use in this aspect of the invention is especially useful in the treatment or alleviation of a tumour cell, e.g. a cancer cell.

Thus, the use may comprise the killing of cells by holding ion channels open with a targeted static magnetic field. Alternatively, the use may comprise the killing of cells via cyclically opening and closing ion channels with a targeted, time-varying magnetic field.

According to a yet further aspect of the invention we provide the use of a magnetisable particle in the manufacture of a system for inducing a therapeutic effect in a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell and magnetically manipulating the magnetisable particle.

In addition we provide the use of a magnetisable particle in the manufacture of a system comprising a therapeutically active agent which may be administered simultaneously, separately or sequentially with the magnetisable particle whilst agonising or antagonising ion channels within the cell.

We also provide the use of a magnetisable particle in the manufacture of a system for targeting a therapeutically active agent to a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell, magnetically manipulating the magnetisable particle and simultaneously, separately or sequentially administering the therapeutically active agent.

According to a yet further aspect of the invention we provide a kit comprising a therapeutically active agent and means for associating a magnetisable particle with a cell.

It will be understood by the skilled that any conventionally known therapeutically active agent or a combination of therapeutically active agents may be utilised in the kit of the invention.

Thus, the kit may comprise a vessel containing a therapeutically active agent, a source of magnetisable particles and instructions for the simultaneous, sequential or separate administration thereof. The kit of the invention may also include other agents known *per se*. The invention may also include the use of a kit as hereinbefore described in the manufacture of a medicament.

The invention will now be described by way of example only and with reference to the accompanying drawings in which Figure 1a) is a schematic representation of the structure of TREK-1 showing the three sites of 12x histidine insertions for tagging magnetic beads for mechanical manipulation;

Figure 1b) illustrates primary human astrocytes with membrane bound RGD coated carboxyl ferromagnetic particles (4μm) (magnification x 1000);

Figure 2 is a schematic of the TREK ion channel showing structure and location of the His. tags present in the protein. Red circles indicate the sites of the His tags at the three sites, the primary loop, the COOH terminus and the NH terminus;

Figure 3 is a representation of the magnetic activation of Trek-1 monitored via downstream changes in intracellular calcium; and

Figure 4 is a representation of the magnetic activation of TREK-1 induces transient rise in intracellular calcium in HEK293 T cells co-transfected with and Flashpericam.

Example 1

Targeting model system

The model system consists of a peristaltic pump connected to tubing which feeds into channels within agar gel blocks. The magnets can be placed at various positions in relation to the channels and the magnetic field and gradient at the target site is measured using an axial Hall probe interfaced to a gaussmeter. The magnetic fields generated by the rare earth magnets will be characterised using a Redcliffe Diagnostics MagScan field mapping system requested for this project. After each experimental run, the gel channel will be excised and assayed for cell capture using staining techniques. Magnetic particle capture will be quantified by performing Superconducting Quantum Interference Device (SQUID) magnetometry measurements on the freeze dried gel blocks. Models may be used to optimize the delivery and targeting parameters, such as magnetic field strength and geometry, magnetic particle characteristics, number of particles per cell, etc.

Example 2

Non-specific membrane deformation using magnetic cytometry

Specifically, scaffolds are seeded with 10^6-10^9 BMSc dependant on scaffold size and cultured for 24 hours prior to placing within the bioreactor. Constructs are then subjected to varying magnetic loading regimes, e.g. 1 hour at 1 Hz frequency with forces ranging from 1-100pN per particle. These parameters are controllable and will allow optimisation of the system for varying cell types and scaffold materials. Following treatment, cells may be removed and subjected to RNA and protein analysis at varying points after activation. Using Western blotting, FACs analysis and quantitative PCR techniques assays may be conducted for osteoblastic transcription factors, such as runx 2 and osterix, alongside matrix proteins, such as osteopontin, collagen type 1, alkaline phosphatase and osteocalcin.

Example 3

Demonstration of new bone formation in animal models to validate the applicability of these magnetic micro and Nanoparticles

Animal trials of this technology support the ability to remotely activate stem cells to promote bone call differentiation and new bone formation by cells held *in vivo* within subcutaneous diffusion chambers using a mouse SCID model. In this way, comparisons can be made with *in vitro* experiments. Targeting of cells to specific tissues *in vivo* may also be advised.

Example 4

Demonstration of in vivo bone formation

Human-derived osteoprogenitors from mesenchymal stem cells may be used. *In vivo* bone formation may be assessed using the subcutaneous implant model in severely compromised immunodeficient (SCID) mice and the diffusion chamber model. This provides a rapid and robust model to validate, *in vivo*, the efficacy for targeting of

magnetic micro- and nanoparticles and provides a clear demonstration of bone formation. The diffusion chamber assay provides unequivocal demonstration of bone formation by implanted cells as opposed to host cells. The subcutaneous implant model remains the industry standard for the assessment of skeletal tissue formation and one of us (RO) has published on the use of both the sc and DC models under a project license to RO (30/1759) for assessment of skeletal tissue engineering[22]. In brief, selected human osteoprogenitor cells will be implanted subcutaneously in SCID mice for four weeks while for diffusion chamber studies, cells and magnetic particle composites will be placed into each diffusion chamber and the chambers implanted intraperitoneally into athymic nude mice (MFI-nu-nu; 4-6 weeks old; Harlan UK Ltd) for 10 weeks. Thereafter, diffusion chambers will be removed, fixed overnight (95% ethanol, 4°C) and embedded undecalcified in poly(hydroxymethylmethacrylate) resin at 4°C. New bone formation will be assessed by histological techniques including frozen, paraffin and methylmethacrylate plastic sections. Assessment of cartilage and bone formed will be by histological examination using toluidine blue Giemsa, alcian blue/sirius red and Safranin-O staining. The model is currently run in Southampton under a project licence to RO (30/1759).

Example 5

Targeting of cells to specific sites *in vivo*

This work will focus on delivery of magnetic particle-loaded cells to specific tissue sites via intra-arterial and intravenous injection. In brief, selected and expanded mesenchymal stem cells will be loaded with magnetic particles and injected by tail vein into anesthesized MF1nu/nu mice. The cells will be localised to a specific target site using external high-gradient NdFeB magnets. Control mice also will be injected, however, no magnet will be used for targeting. Targeting efficiency will be assayed using MRI (magnetic nanoparticles are used as contrast enhancement agents in clinical MR imaging) and SQUID magnetometry analysis of dissected, freeze-dried target tissue after 4, 7 and 14 days.

Claims

1. A method of selectively activating and/or targeting stem cells which enables the cells to then be manipulated mechanically in a remote manner.

2. A method according to claim 1 characterised in that the remote manner is a non-contacting manner and in the case of in vivo activating/targeting specifically from outside the body.

3. A method according to claim 1 characterised in that the method comprises magnetically manipulating a stem cell in vivo or in vitro by the association of a magnetisable particle with a stem cell.

4. A method according to claim 1 characterised in that the method comprises

(i) targeting stem cells to the site of repair and/or holding the cells at that site; and

(ii) conditioning and/or differentiating *in vitro* and/or *in vivo*.

5. A method according to claim 1 characterised in that the method comprises the targeting of stem cells *in vivo*.

6. A method according to claim 1 characterised in that the method comprises the manipulation of human stem cells.

7. A method according to claim 1 characterised in that the method comprises tagging the stem cells with magnetisable nanoparticles which can be delivered to or held at, a particular repair site by external magnetic manipulation.

8. A method according to claim 1 characterised in that the method comprises remote activation of specific stem cell membrane receptors.

9. A method according to claim 1 characterised in that the method comprises deposition of stem cells at a site, retaining the cells at the site and remotely activating the cells *in situ* within a patient.

10. A method according to claim 1 characterised in that the method comprises targeting specific receptors on stem cells for remote activation of transmembrane ion channels in stem cells.

11. A method according to claim 1 characterised in that the method comprises early stage differentiation of cell types.

12. A method according to claim 1 characterised in that the method comprises targeting a variety of stem cell receptor types present in human bone marrow stem cells.

13. A method according to claim 12 characterised in that the stem cell receptor types are selected from mechano-activated ion channels e.g. K+ channels (TREK), calcium channels, integrins and surface membrane binding sites, such as RGD.

14. A method according to claim 13 characterised in that the method comprises targeting receptors for external growth factors (e.g. TGFB and BMP2) which have been shown to activate downstream transcription factors such as Runx2 and Osterix, (critical for stem cell differentiation).

15. A method according to claim 1 characterised in that the stem cells are mesenchymal stem cells.

16. A method according to claim 15 characterised in that the method comprises engraftment of human mesenchymal stem cells at the site of injury or repair.

17. A method according to claim 1 characterised in that the method provides therapeutic treatment.

18. A method according to claim 17 characterised in that the therapeutic treatment is selected from gene therapy and tissue engineering.

19. A method according to claim 18 characterised in that the site is a tissue repair site.

20. A method according to claim 1 characterised in that the at the functional level the stem cell differentiated as a neuronal cell.

21. A method according to claim 1 characterised in that the method comprises stem cell binding, delivery and activation.

22. A method according to claim 1 characterised in that the method comprises using adult primary marrow human stem cells and/or human embryonic stem cells.

23. A method according to claim 1 characterised in that the bioreactor enables forces to be applied to magnetic particles attached to stem cells cultured in vitro within a multi-well 2D system or in vivo a 3D scaffold-based system.

24. A method according to claim 23 characterised in that the mesenchymal stem cells comprise populations selected from osteogenic, chondrogenic and adipogenic populations.

25. A method according to claim 1 characterised in that the method comprises magnetic activated cell sorting (MACS) with a monoclonal antibody.

26. A method according to claim 25 characterised in that the monoclonal antibody is STRO-1.

27. A method according to claim 23 characterised in that the method includes BMSc culture in monolayer, using 3D scaffolds composed of biodegradable polymers.

28. A method according to claim 27 characterised in that the biodegradable polymer is selected from polylactic acid (PLLA) and a collagen gel.

29. A method according to claim 1 characterised in that the method comprises *ex vivo* manipulation of an *in vivo* process.

30. A method according to claim 1 characterised in that the method comprises the activation and/or targeting of a magnetisable particle with a stem cell.

31. A method of magnetically manipulating a stem cell which comprises the association of a magnetisable particle with a cell characterised in that the method comprises agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell.

32. A method according to claims 1 or 31 characterised in that the method includes a differentiation step.

33. A method according to claims 1 or 31 characterised in that the magnetisable particle is associated directly with the stem cell.

34. A method according to claims 1 or 31 characterised in that the method comprises associating the magnetisable particle with an antibody or an enzyme which antibody or enzyme is subsequently associated with the stem cell.

35. A method according to claims 1 or 31 characterised in that the method comprises the introduction of a particle into a stem cell or the attachment of a particle to a stem cell.

36. A method according to claim 35 characterised in that particles are associated intracellularly or extracellularly.

37. A method according to claim 36 characterised in that particles are associated intracellularly.

38. A method according to claim 37 characterised in that the intracellular association comprises association with an internal binding site.

39. A method according to claims 1 or 31 characterised in that the method comprises manipulating a mechanosensitive ion channel in a stem cell characterised in that the method comprises the association of a magnetisable particle with an ion channel, either directly or indirectly.

40. A method according to claim 39 characterised in that particles are associated with the N-terminal region of the ion channel.

41. A method according to claim 39 characterised in that particles are associated with the COOH terminal region of the ion channel.

42. A method according to claim 39 characterised in that the method comprises the remote manipulation of stem cells and/or of agonising or autagonising an ion channel remotely.

43. A method according to claims 1 or 31 characterised in that the method comprises the utilisation of stem cells known to respond to shear stress, cell swelling and membrane stretch and/or external agents.

44. A method according to claim 43 characterised in that the external agent is a fatty acid or a general anaesthetic.

45. A method according to claims 1 or 31 characterised in that the method is incorporated in an application of pain relief, anaesthesia, therapeutics, tissue engineering and repair and/or cancer therapy.

46. A method according to claim 45 characterised in that the stem cell is differentiated to connective or neuronal tissue.

47. A method according to claim 45 characterised in that the stem cell is differentiated to bone, neurons, cardiac cells or any combination thereof.

48. A method according to claim 39 characterised in that the ion channel is a mechanosensitive ion channel.

49. A method according to claim 39 characterised in that the mechanosensitive ion channel has been transfected into a cell.

50. A method according to claim 39 characterised in that the method comprises the use of force resulting in membrane deformation, triggering the opening of the channel or Voltage-gated and ligand-gated ion channels.

51. A method according to claim 50 characterised in that the ion channel is a voltage-gated ion channel.

52. A method according to claim 50 characterised in that the ion channel is a ligand-gated ion channel.

53. A method according to claim 39 characterised in that the ion channel is selected from the group a including sodium channel, potassium channel, calcium channel, chloride channel and a non-selective cation channel or any combination thereof.

54. A method according to claim 53 characterised in that the ion channel is selected from a calcium or a potassium ion channel.

55. A method according to claim 54 characterised in that the ion channel is a potassium ion channel.

56. A method according to claim 55 characterised in that the potassium channel is a TREK-1 channel.

57. A method according to claim 56 characterised in that the method comprises the utilisation of TREK-1 channels in bone cells.

58. A method according to claims 1 or 31 characterised in that the method comprises targeting using an external high gradient rare earth magnet.

59. A method according to claim 58 characterised in that the rare earth magnet is a NdFeB magnet.

60. A method according to claims 1 or 31 characterised in that the magnets produce high field/gradient products which exert a translational force on the magnetic particles loaded onto the cells, holding them at the target site according to the equation:

$$F_{mag} = (X_2 - X_1)V\frac{1}{\mu_o}B(\nabla B)$$

61. A method according to claims 1 or 31 characterised in that the activation comprises remote mechanical activation achieved using a magnetic conditioning bioreactor.

62. A method according to claims 1 or 31 characterised in that the magnetisable particle used in the method of the invention may be inherently magnetic or, alternatively, may be one which reacts in a magnetic field.

63. A method according to claims 1 or 31 characterised in that the magnetisable particle is magnetic.

64. A method according to claim 63 characterised in that the magnetic material is paramagnetic superparamagnetic, ferromagnetic and/or antiferromagnetic,

65. A method according to claim 62 characterised in that the magnetisable material is selected from the group which includes elemental iron (Fe), or a compound thereof, and a chromium compound, or a combination thereof.

66. A method according to claim 65 characterised in that the iron compound is an iron salt.

67. A method according to claim 66 characterised in that the iron salt is selected from the group which includes magnetite (Fe_3O_4), maghemite (γFe_2O_3) and greigite (Fe_3S_4), or any combination thereof.

68. A method according to claim 65 characterised in that the chromium compound is a chromium salt.

69. A method according to claim 68 characterised in that the chromium salt is chromium oxide (CrO_2).

70. A method according to claim 63 characterised in that the magnetic material comprises particles which comprises a magnetic core with a biocompatible coating.

71. A method according to claim 70 characterised in that the biocompatible magnetic nanoparticles comprise a magnetite (Fe_3O_4) and/or maghemite (Fe_2O_3) core with either a silica, dextran, or PVA coating.

72. A method according to claims 1 or 31 characterised in that the particle is a nanoparticle.

73. A method according to claim 72 characterised in that the nanoparticles have a particle size of from 1nm to 10μm.

74. A method according to claim 73 characterised in that the particles have a mean size of 5000 nm or less.

75. A method according to claim 74 characterised in that the particles have a mean size of from 1 nm to 5000 nm.

76. A method according to claim 72 characterised in that the magnetic nanoparticles have a particle size of from 10nm up to a few microns.

77. A method according to claims 1 or 31 characterised in that the coating is functionalized and crosslinked to membrane attachment motifs.

78. A method according to claims 1 or 31 characterised in that the magnetic nanoparticles are modified so as to customise particle internalization frequency, binding efficiency, stability and binding on cell viability and function.

79. A method according to claim 78 characterised in that the modification includes customisation of internal binding sites as well as sites on the outer membrane.

80. A method according to claim 71 characterised in that the particle has a core and a silica shell enveloping the core.

81. A method according to claim 80 characterised in that the particle is selected from those comprising (a) a core comprising a magnetisable particle and (b) a silica shell enveloping the core.

82. A method according to claim 70 characterised in that the particle is a porous particle with multiple magnetic centre within the pores.

83. A method according to claims 1 or 31 characterised in that the method comprises the application of a remote magnetic field on the magnetisable particles.

84. A method according to claim 34 characterised in that the particle is tagged with one or more specific antibodies or protein binding motifs which recognise key cellular elements within a cell.

85. A method according to claim 84 characterised in that the specific antibodies or protein binding motifs are selected from transmembrane extracellular matrix molecules, adhesion molecules or dispersed membrane adhesion proteins or extracellular matrix proteins.

86. A method according to claim 85 characterised in that the transmembrane adhesion molecules are selected from integrins, cadherins, selectins, and immunoglobulins.

87. A method according to claim 86 characterised in that the specific antibodies or protein binding motifs are selected from dispersed membrane adhesion proteins.

88. A method according to claim 87 characterised in that the dispersed membrane adhesion protein is RGD (arginine-glycine-aspartate).

89. A method of treatment of a patient suffering from a disorder in which an ion channel plays a role which comprises the administration to such a patient of magnetisable particles and manipulating stem cell ion channels or the stem cells using a magnetic field external to the body.

90. A method of treatment or alleviation of a tumour cell which comprises a method according to claim 89.

91. A method according to claim 90 characterised in that the tumour cell is a cancer cell.

92. A method of treatment of a patient according to claim 91 characterised in that the method comprises the killing of cells via holding ion channels open with a targeted static magnetic field.

93. A method of treatment of a patient according to claim 91 characterised in that the method comprises the killing of cells via cyclically opening and closing ion channels with a targeted, time-varying magnetic field.

94. A method of treatment according to claim 91 in which a disorder may involve a number of tissues in the body where ion channels play a key role in normal cellular homeostasis.

95. A method according to claim 94 characterised in the cells are cardiac muscle cells.

96. A method according to claim 94 characterised in that the method comprises the treatment of hypertension.

97. A method according to claim 94 characterised in that the method comprises pain relief.

98. A method according to claim 97 characterised in that the method comprises anaesthesia.

99. A method according to claim 98 characterised in that the anaesthesia is localised.

100. A method of treatment of a patient according to claim 89 characterised in that the method comprises tissue and/or bone repair.

101. A method of treatment according to claim 100 characterised in that the cells are selected from ligamentum cells, tenocytes, chondrocytes and other stromal cells (such as chondrocyte progenitor cells).

102. A method of treatment according to claim 100 characterised in that the method comprises the regeneration of tissue or the generation of artificial tissue, such as skin, cartilage, ligament, tendon, muscle or bone.

103. A method of treatment according to claim 100 characterised in that the method comprises the remote activation of ion channels.

104. A method of treatment according to claim 100 characterised in that the method comprises wound healing and/or tissue adhesion.

105. A method of treatment according to claim 100 characterised in that the method comprises bone repair and/or bone growth.

106. A method of treatment according to claim 89 characterised in that the method comprises a dental or veterinary application.

107. A method of treatment according to claim 98 characterised in that the method establishes localised anaesthesia through the action of ion channel modulation by a magnetic field external to the body.

108. A method of treatment according to claim 89 characterised in that the method comprises the use of a magnetic field at a frequency of from 0.1 to 10 Hz.

109. A method of treatment according to claim 89 characterised in that the method comprises the use of a magnetic field will typically have a flux density of from 10 mT to 1400 mT.

110. A method of inducing a therapeutic effect in a stem cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell and magnetically manipulating the magnetisable particle.

111. A method of treatment which comprises the administration of a therapeutically active agent which may be administered simultaneously, separately or sequentially with a magnetisable particle whilst agonising or antagonising ion channels within a stem cell.

112. A method of targeting a therapeutically active agent to a stem cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell, magnetically manipulating the magnetisable

particle and simultaneously, separately or sequentially administering the therapeutically active agent.

113. The use of a magnetisable particle in a method of magnetically manipulating a stem cell wherein the method comprises the association of a magnetisable particle with a cell.

114. The use according to claim 113 characterised in that the use comprises selectively activating and/or targeting stem cells which enables the cells to then be manipulated mechanically in a remote manner.

115. The use according to claim 113 characterised in that the remote manner is a non-contacting manner and in the case of in vivo activating/targeting specifically from outside the body.

116. The use according to claim 113 characterised in that the use comprises magnetically manipulating a stem cell *in vivo* or *in vitro* by the association of a magnetisable particle with a stem cell.

117. The use according to claim 113 characterised in that the use comprises

(i) targeting stem cells to the site of repair and/or holding the cells at that site; and

(ii) conditioning and/or differentiating *in vitro* and/or *in vivo*.

118. The use according to claim 113 characterised in that the use comprises the targeting of stem cells *in vivo*.

119. The use according to claim 113 characterised in that the use comprises the manipulation of human stem cells.

120. The use according to claim 113 characterised in that the use comprises tagging the stem cells with magnetisable nanoparticles which can be delivered to or held at, a particular repair site by external magnetic manipulation.

121. The use according to claim 113 characterised in that the use comprises remote activation of specific stem cell membrane receptors.

122. The use according to claim 113 characterised in that the use comprises deposition of stem cells at a site, retaining the cells at the site and remotely activating the cells *in situ* within a patient.

123. The use according to claim 113 characterised in that the use comprises targeting specific receptors on stem cells for remote activation of transmembrane ion channels in stem cells.

124. The use according to claim 113 characterised in that the use comprises early stage differentiation of cell types.

125. The use according to claim 113 characterised in that the use comprises targeting a variety of stem cell receptor types present in human bone marrow stem cells.

126. The use according to claim 125 characterised in that the stem cell receptor types are selected from mechano-activated ion channels e.g. K+ channels (TREK), calcium channels, integrins and surface membrane binding sites, such as RGD.

127. The use according to claim 126 characterised in that the use comprises targeting receptors for external growth factors (e.g. TGFB and BMP2) which have been shown to activate downstream transcription factors such as Runx2 and Osterix, (critical for stem cell differentiation).

128. The use according to claim 1 characterised in that the stem cells are mesenchymal stem cells.

129. The use according to claim 128 characterised in that the use comprises engraftment of human mesenchymal stem cells at the site of injury or repair.

130. The use according to claim 113 characterised in that the use provides therapeutic treatment.

131. The use according to claim 130 characterised in that the therapeutic treatment is selected from gene therapy and tissue engineering.

132. The use according to claim 131 characterised in that the site is a tissue repair site.

133. The use according to claim 113 characterised in that the at the functional level the stem cell differentiated as a neuronal cell.

134. The use according to claim 113 characterised in that the use comprises stem cell binding, delivery and activation.

135. The use according to claim 113 characterised in that the use comprises using adult primary marrow human stem cells and/or human embryonic stem cells.

136. The use according to claim 113 characterised in that the bioreactor enables forces to be applied to magnetic particles attached to stem cells cultured in vitro within a multi-well 2D system or in vivo a 3D scaffold-based system.

137. The use according to claim 136 characterised in that the mesenchymal stem cells comprise populations selected from osteogenic, chondrogenic and adipogenic populations.

138. The use according to claim 1 characterised in that the use comprises magnetic activated cell sorting (MACS) with a monoclonal antibody.

139. The use according to claim 138 characterised in that the monoclonal antibody is STRO-1.

140. The use according to claim 136 characterised in that the use includes BMSc culture in monolayer, using 3D scaffolds composed of biodegradable polymers.

141. The use according to claim 140 characterised in that the biodegradable polymer is selected from polylactic acid (PLLA) and a collagen gel.

142. The use according to claim 113 characterised in that the use comprises *ex vivo* manipulation of an *in vivo* process.

143. The use according to claim 113 characterised in that the use comprises the activation and/or targeting of a magnetisable particle with a stem cell.

144. The use of a magnetisable particle in the manufacture of a therapy that comprises agonising or antagonising ion channels within a stem cell by the association of the magnetisable particle with a stem cell.

145. The use according to claims 113 or 144 characterised in that the use includes a differentiation step.

146. The use according to claims 113 or 144 characterised in that the magnetisable particle is associated directly with the stem cell.

147. The use according to claims 113 or 144 characterised in that the use comprises associating the magnetisable particle with an antibody or an enzyme which antibody or enzyme is subsequently associated with the stem cell.

148. The use according to claims 113 or 144 characterised in that the use comprises the introduction of a particle into a stem cell or the attachment of a particle to a stem cell.

149. The use according to claim 148 characterised in that particles are associated intracellularly or extracellularly.

150. The use according to claim 149 characterised in that particles are associated intracellularly.

151. The use according to claim 150 characterised in that the intracellular association comprises association with an internal binding site.

152. The use according to claim 113 or 144 characterised in that the use comprises manipulating a mechanosensitive ion channel in a stem cell characterised in that the use comprises the association of a magnetisable particle with an ion channel, either directly or indirectly.

153. The use according to claim 152 characterised in that particles are associated with the N-terminal region of the ion channel.

154. The use according to claim 152 characterised in that particles are associated with the COOH terminal region of the ion channel.

155. The use according to claim 152 characterised in that the use comprises the remote manipulation of stem cells and/or of agonising or autagonising an ion channel remotely.

156. The use according to claim 113 or 144 characterised in that the use comprises the utilisation of stem cells known to respond to shear stress, cell swelling and membrane stretch and/or external agents.

157. The use according to claim 156 characterised in that the external agent is a fatty acid or a general anaesthetic.

158. The use according to claim 113 or 144 characterised in that the use is incorporated in an application of pain relief, anaesthesia, therapeutics, tissue engineering and repair and/or cancer therapy.

159. The use according to claim 158 characterised in that the stem cell is differentiated to connective or neuronal tissue.

160. The use according to claim 158 characterised in that the stem cell is differentiated to bone, neurons, cardiac cells or any combination thereof.

161. The use according to claim 152 characterised in that the ion channel is a mechanosensitive ion channel.

162. The use according to claim 152 characterised in that the mechanosensitive ion channel has been transfected into a cell.

163. The use according to claim 152 characterised in that the use comprises the use of force resulting in membrane deformation, triggering the opening of the channel or Voltage-gated and ligand-gated ion channels.

164. The use according to claims 163 characterised in that the ion channel is a voltage-gated ion channel.

165. The use according to claims 163 characterised in that the ion channel is a ligand-gated ion channel.

166. The use according to claim 152 characterised in that the ion channel is selected from the group a including sodium channel, potassium channel, calcium channel, chloride channel and a non-selective cation channel or any combination thereof.

167. The use according to claim 166 characterised in that the ion channel is selected from a calcium or a potassium ion channel.

168. The use according to claim 167 characterised in that the ion channel is a potassium ion channel.

169. The use according to claim 168 characterised in that the potassium channel is a TREK-1 channel.

170. The use according to claim 169 characterised in that the use comprises the utilisation of TREK-1 channels in bone cells.

171. The use according to claims 113 or 144 characterised in that the use comprises targeting using an external high gradient rare earth magnet.

172. The use according to claim 171 characterised in that the rare earth magnet is a NdFeB magnet.

173. The use according to claims 113 or 144 characterised in that the magnets produce high field/gradient products which exert a translational force on the

magnetic particles loaded onto the cells, holding them at the target site according to the equation:

$$F_{mag} = (X_2 - X_1)V\frac{1}{\mu_o}B(\nabla B)$$

174. The use according to claims 113 or 144 characterised in that the activation comprises remote mechanical activation achieved using a magnetic conditioning bioreactor.

175. The use according to claims 113 or 144 characterised in that the magnetisable particle used in the use of the invention may be inherently magnetic or, alternatively, may be one which reacts in a magnetic field.

176. The use according to claims 113 or 144 characterised in that the magnetisable particle is magnetic.

177. The use according to claim 176 characterised in that the magnetic material is paramagnetic superparamagnetic, ferromagnetic and/or antiferromagnetic,

178. The use according to claim 175 characterised in that the magnetisable material is selected from the group which includes elemental iron (Fe), or a compound thereof, and a chromium compound, or a combination thereof.

179. The use according to claim 178 characterised in that the iron compound is an iron salt.

180. The use according to claim 179 characterised in that the iron salt is selected from the group which includes magnetite (Fe_3O_4), maghemite (γFe_2O_3) and greigite (Fe_3S_4), or any combination thereof.

181. The use according to claim 178 characterised in that the chromium compound is a chromium salt.

182. The use according to claim 181 characterised in that the chromium salt is chromium oxide (CrO_2).

183. The use according to claim 176 characterised in that the magnetic material comprises particles which comprises a magnetic core with a biocompatible coating.

184. The use according to claim 183 characterised in that the biocompatible magnetic nanoparticles comprise a magnetite (Fe_3O_4) and/or maghemite (Fe_2O_3) core with either a silica, dextran, or PVA coating.

185. The use according to claims 113 or 144 characterised in that the particle is a nanoparticle.

186. The use according to claim 185 characterised in that the nanoparticles have a particle size of from 1nm to 10μm.

187. The use according to claim 187 characterised in that the particles have a mean size of 5000 nm or less.

188. The use according to claim 187 characterised in that the particles have a mean size of from 1 nm to 5000 nm.

189. The use according to claim 185 characterised in that the magnetic nanoparticles have a particle size of from 10nm up to a few microns.

190. The use according to claims 113 or 144 characterised in that the coating is functionalized and crosslinked to membrane attachment motifs.

191. The use according to claims 113 or 144 characterised in that the magnetic nanoparticles are modified so as to customise particle internalization frequency, binding efficiency, stability and binding on cell viability and function.

192. The use according to claim 191 characterised in that the modification includes customisation of internal binding sites as well as sites on the outer membrane.

193. The use according to claim 184 characterised in that the particle has a core and a silica shell enveloping the core.

194. The use according to claim 193 characterised in that the particle is selected from those comprising (a) a core comprising a magnetisable particle and (b) a silica shell enveloping the core.

195. The use according to claim 183 characterised in that the particle is a porous particle with multiple magnetic centre within the pores.

196. The use according to claims 113 or 144 characterised in that the use comprises the application of a remote magnetic field on the magnetisable particles.

197. The use according to claim 147 characterised in that the particle is tagged with one or more specific antibodies or protein binding motifs which recognise key cellular elements within a cell.

198. The use according to claim 197 characterised in that the specific antibodies or protein binding motifs are selected from transmembrane extracellular matrix molecules, adhesion molecules or dispersed membrane adhesion proteins or extracellular matrix proteins.

199. The use according to claim 198 characterised in that the transmembrane adhesion molecules are selected from integrins, cadherins, selectins, and immunoglobulins.

200. The use according to claim 199 characterised in that the specific antibodies or protein binding motifs are selected from dispersed membrane adhesion proteins.

201. The use according to claim 200 characterised in that the dispersed membrane adhesion protein is RGD (arginine-glycine-aspartate).

202. The use of a magnetisable particle in association with a stem cell in the manufacture of a therapy for the treatment of a patient suffering from a disorder in which an ion channel plays a role which comprises the administration to such a patient of magnetisable particles and manipulating the stem cell ion channels or the stem cells using a magnetic field external to the body.

203. The use of a magnetisable particle in the manufacture of a system for targeting a therapeutically active agent to a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell, magnetically manipulating the magnetisable particle and simultaneously, separately or sequentially administering the therapeutically active agent.

204. A kit comprising a therapeutically active agent and means for associating a magnetisable particle with a cell.

205. A method or use substantially as described with reference to the accompanying drawings.

PCT/GB2004/005156